Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 345

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial

Open access
Brown, Christine E., Hibbard, Jonathan C., Alizadeh, Darya, Blanchard, M. Suzette, Natri, Heini M., Wang, Dongrui, Ostberg, Julie R., Aguilar, Brenda, Wagner, Jamie R., Paul, Jinny A., Starr, Renate, Wong, Robyn A., Chen, Wuyang, Shulkin, Noah, Aftabizadeh, Maryam, Filippov, Aleksandr, Chaudhry, Ammar, Ressler, Julie A., Kilpatrick, Julie, Myers-McNamara, Paige, Chen, Mike, Wang, Leo D., Rockne, Russell C., Georges, Joseph, Portnow, Jana, Barish, Michael E., D’Apuzzo, Massimo, Banovich, Nicholas E., Forman, Stephen J., Badie, Behnam·2024·Nature Medicine

Abstract

Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current therapies. Here we report a completed phase I trial evaluating IL-13Rα2-targeted CAR-T cells in 65 patients with recurrent high-grade glioma, the majority being recurrent glioblastoma (rGBM). Primary objectives were safety and feasibility, maximum tolerated dose/maximum feasible dose and a recommended phase 2 dose plan. Secondary objectives included overall survival, disease response, cytokine dynamics and tumor immune contexture biomarkers. This trial evolved to evaluate three routes of locoregional T cell administration (intratumoral (ICT), intraventricular (ICV) and dual ICT/ICV) and two manufacturing platforms, culminating in arm 5, which utilized dual ICT/ICV delivery and an optimized manufacturing process. Locoregional CAR-T cell administration was feasible and well tolerated, and as there were no dose-limiting toxicities across all arms, a maximum tolerated dose was not determined. Probable treatment-related grade 3+ toxicities were one grade 3 encephalopathy and one grade 3 ataxia. A clinical maximum feasible dose of 200 × 10 6 CAR-T cells per infusion cycle was achieved for arm 5; however, other arms either did not test or achieve this dose due to manufacturing feasibility. A recommended phase 2 dose will be refined in future studies based on data from this trial. Stable disease or better was achieved in 50% (29/58) of patients, with two partial responses, one complete response and a second complete response after additional CAR-T cycles off protocol. For rGBM, median overall survival for all patients was 7.7 months and for arm 5 was 10.2 months. Central nervous system increases in inflammatory cytokines, including IFNγ, CXCL9 and CXCL10, were associated with CAR-T cell administration and bioactivity. Pretreatment intratumoral CD3 T cell levels were positively associated with survival. These findings demonstrate that locoregional IL-13Rα2-targeted CAR-T therapy is safe with promising clinical activity in a subset of patients. ClinicalTrials.gov Identifier: NCT02208362 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-024-02875-1

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

See all 345

Metadata

Authors
Brown, C. E., Hibbard, J. C., Alizadeh, D., Blanchard, M. S., Natri, H. M., Wang, D., Ostberg, J. R., Aguilar, B., Wagner, J. R., Paul, J. A., Starr, R., Wong, R. A., Chen, W., Shulkin, N., Aftabizadeh, M., Filippov, A., Chaudhry, A., Ressler, J. A., Kilpatrick, J., Myers-McNamara, P., Chen, M., Wang, L. D., Rockne, R. C., Georges, J., Portnow, J., Barish, M. E., D’Apuzzo, M., Banovich, N. E., Forman, S. J., & Badie, B.
Venue
Nature Medicine
Published
2024-03-07
Volume
30
Issue
4
Pages
1001-1012
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4392560879
Cited by
345
References
68
FWCI
52.79
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. https://app.cochat.ai/papers/10.1038/s41591-024-02875-1
The paper
Brown, C. E., Hibbard, J. C., Alizadeh, D., Blanchard, M. S., Natri, H. M., Wang, D., Ostberg, J. R., Aguilar, B., Wagner, J. R., Paul, J. A., Starr, R., Wong, R. A., Chen, W., Shulkin, N., Aftabizadeh, M., Filippov, A., Chaudhry, A., Ressler, J. A., Kilpatrick, J., . . . Badie, B. (2024). Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nature Medicine. https://doi.org/10.1038/s41591-024-02875-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.